Viracta Therapeutics Performance
| VIRXDelisted Stock | USD 0.03 0 7.38% |
The entity has a beta of -1.9, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Viracta Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Viracta Therapeutics is expected to outperform it. At this point, Viracta Therapeutics has a negative expected return of -5.33%. Please make sure to validate Viracta Therapeutics' value at risk, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if Viracta Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 36.8 M |
Viracta |
Viracta Therapeutics Relative Risk vs. Return Landscape
If you would invest 25.00 in Viracta Therapeutics on December 24, 2024 and sell it today you would lose (21.99) from holding Viracta Therapeutics or give up 87.96% of portfolio value over 90 days. Viracta Therapeutics is currently does not generate positive expected returns and assumes 16.0562% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Viracta, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Viracta Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viracta Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Viracta Therapeutics, and traders can use it to determine the average amount a Viracta Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3318
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VIRX |
Estimated Market Risk
| 16.06 actual daily | 96 96% of assets are less volatile |
Expected Return
| -5.33 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.33 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Viracta Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Viracta Therapeutics by adding Viracta Therapeutics to a well-diversified portfolio.
Viracta Therapeutics Fundamentals Growth
Viracta Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Viracta Therapeutics, and Viracta Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Viracta Pink Sheet performance.
| Return On Equity | -2.09 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | (3.02 M) | ||||
| Shares Outstanding | 39.74 M | ||||
| Price To Earning | 2.54 X | ||||
| Price To Book | 3.00 X | ||||
| EBITDA | (46.86 M) | ||||
| Cash And Equivalents | 83.14 M | ||||
| Cash Per Share | 2.21 X | ||||
| Total Debt | 25.56 M | ||||
| Debt To Equity | 0.07 % | ||||
| Book Value Per Share | 0.33 X | ||||
| Cash Flow From Operations | (39.89 M) | ||||
| Earnings Per Share | (1.10) X | ||||
| Total Asset | 56.69 M | ||||
| Retained Earnings | (265.93 M) | ||||
About Viracta Therapeutics Performance
Evaluating Viracta Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Viracta Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Viracta Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California. Viracta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people.Things to note about Viracta Therapeutics performance evaluation
Checking the ongoing alerts about Viracta Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Viracta Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Viracta Therapeutics is not yet fully synchronised with the market data | |
| Viracta Therapeutics generated a negative expected return over the last 90 days | |
| Viracta Therapeutics has high historical volatility and very poor performance | |
| Viracta Therapeutics has some characteristics of a very speculative penny stock | |
| Viracta Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (51.06 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Viracta Therapeutics currently holds about 83.14 M in cash with (39.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Viracta Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Viracta Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Viracta Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Viracta Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Viracta Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Viracta Therapeutics' pink sheet. These opinions can provide insight into Viracta Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Viracta Pink Sheet
If you are still planning to invest in Viracta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viracta Therapeutics' history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |